Company news

Telo Genomics Corp. news in 2025

Telo Genomics Corp.'s news releases, calls and decks from 2025, newest first.

View company

Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

December 18, 2025

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

December 11, 2025

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

December 10, 2025

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th

December 8, 2025

Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025

November 13, 2025

American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition

October 9, 2025

Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update

September 30, 2025

Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

September 19, 2025

Telo Geonomics Announces Engagement of Investor Relations Service Provider

September 8, 2025

OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing

August 8, 2025

Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference

August 5, 2025

International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

July 24, 2025

Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President

June 30, 2025

Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

June 18, 2025

Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)

May 27, 2025

European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress

May 15, 2025

Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025

April 10, 2025

Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

April 4, 2025

Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors

March 12, 2025

Telo Genomics Announces Expanded Partnership with Trusted Health Advisors

February 27, 2025

Decks in 2025